Inecalcitol

Drug Profile

Inecalcitol

Alternative Names: TX-522

Latest Information Update: 11 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ghent University; Katholieke Universiteit Leuven
  • Developer Hybrigenics
  • Class Alkynes; Antipsoriatics; Secosteroids; Small molecules; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Prostate cancer
  • Preclinical Haematological malignancies; Multiple myeloma
  • Suspended Psoriasis

Most Recent Events

  • 03 Apr 2017 Preclinical trials in Multiple myeloma in France (unspecified route) before April 2017
  • 03 Apr 2017 Updated pharmacodynamics data from a preclinical trial in Acute myeloid leukaemia (PO) and Multiple myeloma presented at the American Association for Cancer Research (AACR-2017)
  • 08 Dec 2016 Updated pharmacodynamics data from a preclinical trial in Multiple myeloma and Acute myeloid leukaemia presented at the 58th Annual Meeting of the American Society of Hematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top